Long-term efficacy and safety of extracorporeal shock wave therapy (Li-ESWT) protocols in the treatment of chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) patients

Figures & data

Table 1. Demographic characteristics.

	Mean	SD	Min	Max	N	%
Age	45.54	8.32	22	58
BMI	28.72	6.64	19.98	38.52
CP type
IIIa					60	46.5
IIIb					69	53.5
Total PSA	1.34	1.53	0.1	7.33
Prostate volume	31.02	14.53	16	80
Session number
6					51	39.5
12					78	60.5
Baseline
IIEF-EF	18.19	3.92	8	24
IPSS	12.08	5.38	4	31
NIH-CPSI	19.88	5.62	6	28
Posttreatment 3rd month
IIEF-EF	20.41	3.59	10	25
IPSS	4.97	2.31	1	8
NIH-CPSI	4.00	1.39	2	6
Posttreatment 12th month
IIEF-EF	20.92	2.86	12	25
IPSS	5.81	2.96	1	16
NIH-CPSI	5.23	2.16	2	10

Table 2. Comparison between pretreatment and posttreatment scores.

	0–3 Difference	p	0–12 Difference	p	3–12 Difference	p
IIEF-EF	2.22 ± 3.31	<0.001	2.74 ± 2.37	<0.001	0.51 ± 2.67	0.032
IPSS	−7.11 ± 4.39	<0.001	−6.27 ± 3.77	<0.001	0.84 ± 1.91	<0.001
NIH-CPSI	−15.88 ± 5.26	<0.001	−14.64 ± 4.93	<0.001	1.23 ± 2.36	<0.001

Wilcoxon test.

Table 3. Comparison between 6 sessions and 12 sessions of ESWT.

	Posttreatment 3rd month			Posttreatment 12th month
	6 Sessions	12 Sessions	p Value	6 Sessions	12 Sessions	p Value
IIEF-EF	20.02 ± 3.42	20.67 ± 3.70	0.319	21.20 ± 2.48	20.74 ± 3.08	0.381
IPSS	5.67 ± 2.30	4.51 ± 2.21	0.005	6.27 ± 3.04	5.50 ± 2.89	0.147
NIH-CPSI	4.10 ± 1.43	3.94 ± 1.36	0.518	4.55 ± 1.85	5.68 ± 2.24	0.003

Independent sample t-test.